<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01308268</url>
  </required_header>
  <id_info>
    <org_study_id>IIET-05</org_study_id>
    <nct_id>NCT01308268</nct_id>
  </id_info>
  <brief_title>Management of Soil-transmitted Helminthiasis and Strongyloidiasis</brief_title>
  <official_title>Community-based Approach for the Management of Soil-transmitted Helminthiasis in General and Strongyloidiasis in Particular in a Highly Endemic Area</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Nacional de Salta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación Mundo Sano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Albert B. Sabin Vaccine Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad Nacional de Salta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The general purpose of the project is to analyse soil-transmitted helminthiases (STH) in a
      highly endemic area in northern Argentina with a multidisciplinary approach. The specific
      objectives are to evaluate the local epidemiology of STH, validate a new diagnostic serology
      method for S. stercoralis and evaluate the efficacy and safety of a mass drug administration
      regimen with albendazole and ivermectin.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">April 2012</completion_date>
  <primary_completion_date type="Anticipated">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of local epidemiology of soil-transmitted helminthiases and impact of a mass drug treatment anti-helminthic strategy</measure>
    <time_frame>15 months</time_frame>
    <description>Evaluate local epidemiology of STH: frequency of species, prevalence and intensity of infections, groups more affected, morbidity.
Evaluate the efficacy of a single-dose anti-helminthic regimen for community treatments: albendazole 400 mg + ivermectin 200 mcg/kg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Validate serology methods for diagnosis of S. stercoralis infection</measure>
    <time_frame>15 months</time_frame>
    <description>Compare sensibility, specificity and predictive values of serology for S.stercoralis (ELISA-NIE) with traditional coproparasitological methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the tolerability and safety of the combination of ivermectin and albendazole</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Helminthiasis</condition>
  <condition>Strongyloides Stercoralis Infection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin + Albendazole</intervention_name>
    <description>Ivermectin: 200µg/kg, single dose, PO + Albendazole 200 (children between 12 and 23 months) or 400 mg (&gt;= 2 years old) single dose, PO</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All persons that are living in the working area at the time of the intervention and
             wish to participate in the study.

        Exclusion Criteria:

          1. All persons that live within the study area but do not want to participate in the
             study.

          2. Pregnant women or women who are likely pregnant.

          3. Women during the first post-partum week if they are breastfeeding.

          4. Children who weigh less than 15 kg.

          5. Persons with a history of hypersensitivity or intolerance to ivermectin, albendazole
             or to the components that make up those drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alejandro Krolewiecki, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Nacional de Salta, Instituto de Investigación en Enfermedades Tropicales</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alejandro Krolewiecki, MD, PhD</last_name>
    <phone>+54-11-45531369</phone>
    <email>alekrol@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>María E Socías, MD</last_name>
    <phone>+54-11-4803-2298</phone>
    <email>eugenia_socias@yahoo.com.ar</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto de Investigación en Enfermedades Tropicales, Universidad Nacional de Salta</name>
      <address>
        <city>Orán</city>
        <state>Salta</state>
        <zip>4530</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2011</study_first_submitted>
  <study_first_submitted_qc>March 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2011</study_first_posted>
  <last_update_submitted>March 3, 2011</last_update_submitted>
  <last_update_submitted_qc>March 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Alejandro Krolewiecki</name_title>
    <organization>Instituto de Investigaciones en Enfermedades Tropicales-Universidad Nacional de Salta</organization>
  </responsible_party>
  <keyword>STH</keyword>
  <keyword>Soil-transmitted Helminthiasis</keyword>
  <keyword>mass drug administration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Helminthiasis</mesh_term>
    <mesh_term>Strongyloidiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albendazole</mesh_term>
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

